Studies on levamisole-induced agranulocytosis

J. S. Thompson, J. M. Herbick, Lynell Warren Klassen, C. D. Severson, V. L. Overlin, J. W. Blaschke, M. A. Silverman, C. L. Vogel

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Widespread clinical trials of laevo-tetramisole (levamisole) as an immunopotentiating agent in rheumatoid arthritis, metastatic carcinoma, and immunodeficiency states have been complicated by agranulocytosis (AGC) in 2.5%-13% of patients. Other than a relationship with prolonged high dosage, very little is known regarding the pathogenesis of levamisole-induced AGC. Whereas leukoagglutination was negative, fluorochromatic microgranulocytotoxicity (GCY) tests were positive with serum from 10 of 10 acutely neutropenic patients. The antibody was IgM, reacted with 100% of unrelated granulocytes, but not with T or B lymphocytes. Some sera also reacted with monocytes and the myeloid cell line, K-562. Tests for antigen-antibody complexes or cold autoantibodies were negative. Although clinical evidence strongly suggests a haptene (drug) mechanism, in vitro mixing experiments were also negative. An alternative choice parallels the model of aldomet-induced Coombs'-positive hemolytic anemia. Finally, GCY first became positive 2-3 mo prior to the onset of AGC in two patients, suggesting the possibility of identifying those at risk well before the onset of neutropenia.

Original languageEnglish (US)
Pages (from-to)388-396
Number of pages9
JournalBlood
Volume56
Issue number3
StatePublished - Dec 1 1980

Fingerprint

Tetramisole
Agranulocytosis
Methyldopa
Lymphocytes
Antigen-Antibody Complex
Autoantibodies
Immunoglobulin M
Hemolytic Anemia
Cells
Myeloid Cells
Neutropenia
Serum
Granulocytes
Antibodies
Monocytes
Rheumatoid Arthritis
B-Lymphocytes
Clinical Trials
Pharmaceutical Preparations
Carcinoma

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Thompson, J. S., Herbick, J. M., Klassen, L. W., Severson, C. D., Overlin, V. L., Blaschke, J. W., ... Vogel, C. L. (1980). Studies on levamisole-induced agranulocytosis. Blood, 56(3), 388-396.

Studies on levamisole-induced agranulocytosis. / Thompson, J. S.; Herbick, J. M.; Klassen, Lynell Warren; Severson, C. D.; Overlin, V. L.; Blaschke, J. W.; Silverman, M. A.; Vogel, C. L.

In: Blood, Vol. 56, No. 3, 01.12.1980, p. 388-396.

Research output: Contribution to journalArticle

Thompson, JS, Herbick, JM, Klassen, LW, Severson, CD, Overlin, VL, Blaschke, JW, Silverman, MA & Vogel, CL 1980, 'Studies on levamisole-induced agranulocytosis', Blood, vol. 56, no. 3, pp. 388-396.
Thompson JS, Herbick JM, Klassen LW, Severson CD, Overlin VL, Blaschke JW et al. Studies on levamisole-induced agranulocytosis. Blood. 1980 Dec 1;56(3):388-396.
Thompson, J. S. ; Herbick, J. M. ; Klassen, Lynell Warren ; Severson, C. D. ; Overlin, V. L. ; Blaschke, J. W. ; Silverman, M. A. ; Vogel, C. L. / Studies on levamisole-induced agranulocytosis. In: Blood. 1980 ; Vol. 56, No. 3. pp. 388-396.
@article{d70cfec1c24044e0855775d747e7c8dc,
title = "Studies on levamisole-induced agranulocytosis",
abstract = "Widespread clinical trials of laevo-tetramisole (levamisole) as an immunopotentiating agent in rheumatoid arthritis, metastatic carcinoma, and immunodeficiency states have been complicated by agranulocytosis (AGC) in 2.5{\%}-13{\%} of patients. Other than a relationship with prolonged high dosage, very little is known regarding the pathogenesis of levamisole-induced AGC. Whereas leukoagglutination was negative, fluorochromatic microgranulocytotoxicity (GCY) tests were positive with serum from 10 of 10 acutely neutropenic patients. The antibody was IgM, reacted with 100{\%} of unrelated granulocytes, but not with T or B lymphocytes. Some sera also reacted with monocytes and the myeloid cell line, K-562. Tests for antigen-antibody complexes or cold autoantibodies were negative. Although clinical evidence strongly suggests a haptene (drug) mechanism, in vitro mixing experiments were also negative. An alternative choice parallels the model of aldomet-induced Coombs'-positive hemolytic anemia. Finally, GCY first became positive 2-3 mo prior to the onset of AGC in two patients, suggesting the possibility of identifying those at risk well before the onset of neutropenia.",
author = "Thompson, {J. S.} and Herbick, {J. M.} and Klassen, {Lynell Warren} and Severson, {C. D.} and Overlin, {V. L.} and Blaschke, {J. W.} and Silverman, {M. A.} and Vogel, {C. L.}",
year = "1980",
month = "12",
day = "1",
language = "English (US)",
volume = "56",
pages = "388--396",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "3",

}

TY - JOUR

T1 - Studies on levamisole-induced agranulocytosis

AU - Thompson, J. S.

AU - Herbick, J. M.

AU - Klassen, Lynell Warren

AU - Severson, C. D.

AU - Overlin, V. L.

AU - Blaschke, J. W.

AU - Silverman, M. A.

AU - Vogel, C. L.

PY - 1980/12/1

Y1 - 1980/12/1

N2 - Widespread clinical trials of laevo-tetramisole (levamisole) as an immunopotentiating agent in rheumatoid arthritis, metastatic carcinoma, and immunodeficiency states have been complicated by agranulocytosis (AGC) in 2.5%-13% of patients. Other than a relationship with prolonged high dosage, very little is known regarding the pathogenesis of levamisole-induced AGC. Whereas leukoagglutination was negative, fluorochromatic microgranulocytotoxicity (GCY) tests were positive with serum from 10 of 10 acutely neutropenic patients. The antibody was IgM, reacted with 100% of unrelated granulocytes, but not with T or B lymphocytes. Some sera also reacted with monocytes and the myeloid cell line, K-562. Tests for antigen-antibody complexes or cold autoantibodies were negative. Although clinical evidence strongly suggests a haptene (drug) mechanism, in vitro mixing experiments were also negative. An alternative choice parallels the model of aldomet-induced Coombs'-positive hemolytic anemia. Finally, GCY first became positive 2-3 mo prior to the onset of AGC in two patients, suggesting the possibility of identifying those at risk well before the onset of neutropenia.

AB - Widespread clinical trials of laevo-tetramisole (levamisole) as an immunopotentiating agent in rheumatoid arthritis, metastatic carcinoma, and immunodeficiency states have been complicated by agranulocytosis (AGC) in 2.5%-13% of patients. Other than a relationship with prolonged high dosage, very little is known regarding the pathogenesis of levamisole-induced AGC. Whereas leukoagglutination was negative, fluorochromatic microgranulocytotoxicity (GCY) tests were positive with serum from 10 of 10 acutely neutropenic patients. The antibody was IgM, reacted with 100% of unrelated granulocytes, but not with T or B lymphocytes. Some sera also reacted with monocytes and the myeloid cell line, K-562. Tests for antigen-antibody complexes or cold autoantibodies were negative. Although clinical evidence strongly suggests a haptene (drug) mechanism, in vitro mixing experiments were also negative. An alternative choice parallels the model of aldomet-induced Coombs'-positive hemolytic anemia. Finally, GCY first became positive 2-3 mo prior to the onset of AGC in two patients, suggesting the possibility of identifying those at risk well before the onset of neutropenia.

UR - http://www.scopus.com/inward/record.url?scp=0019220610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019220610&partnerID=8YFLogxK

M3 - Article

VL - 56

SP - 388

EP - 396

JO - Blood

JF - Blood

SN - 0006-4971

IS - 3

ER -